Cibus (NASDAQ:CBUS) Announces Quarterly Earnings Results

Cibus (NASDAQ:CBUS) released its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.10), FiscalAI reports. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.70 million. Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%.

Here are the key takeaways from Cibus’ conference call:

• Revenue increased 35% year to date to $2.7 million, driven by Sustainable Ingredients collaboration agreements, while R&D and SG&A expenses declined by nearly $5 million year over year.
• Cibus expects additional scale-up orders for its biofragrance program in the second half of 2026 and estimates a potential $20 million–$40 million annual revenue opportunity when fully commercialized.
• The company pushed its expected initial Latin American rice commercialization from late 2027 to 2028; U.S. commercialization remains targeted for 2029, and royalties are not expected to begin until 2028.
• Cibus highlighted expanding rice partnerships, including Interoc’s increase from two traits to five, and described a potential rice royalty opportunity exceeding $200 million annually at peak adoption across the Americas.
• Cibus had $20.4 million in cash at June 30 and expects funding only into early Q1 2027, while its projected annualized net cash usage exiting 2026 increased to approximately $35 million as it invests in technology and personnel.

Cibus Stock Up 0.5%

NASDAQ CBUS traded up $0.01 during trading on Thursday, hitting $1.90. 240,835 shares of the company’s stock were exchanged, compared to its average volume of 162,350. Cibus has a fifty-two week low of $1.09 and a fifty-two week high of $4.19. The stock’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $1.97.

Institutional Investors Weigh In On Cibus

Several hedge funds and other institutional investors have recently made changes to their positions in CBUS. Jane Street Group LLC acquired a new stake in shares of Cibus during the second quarter valued at about $207,000. Corient Private Wealth LLC acquired a new position in shares of Cibus in the fourth quarter valued at approximately $145,000. Squarepoint Ops LLC bought a new position in Cibus in the 3rd quarter valued at approximately $62,000. AQR Capital Management LLC acquired a new stake in Cibus during the 1st quarter worth approximately $73,000. Finally, Renaissance Technologies LLC boosted its position in Cibus by 74.4% during the 4th quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock worth $121,000 after buying an additional 29,600 shares during the period. 33.81% of the stock is owned by institutional investors.

Analyst Ratings Changes

CBUS has been the topic of several analyst reports. Weiss Ratings lowered shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Wall Street Zen upgraded Cibus from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.